The Department of Pharmacy, Medical Supplies, Equipment, and Supplies, Ministry of Health of Hamad government has warned all ...
FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...
The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEX™ ...
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab ...
Monotherapy in immunotherapy-ineligible patients improved median PFS to 9.7 vs 6.9 months versus physician’s-choice chemotherapy, with 50% vs 47% objective response rates. Combination therapy in PD-L1 ...
Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) treatment space, notching a Keytruda combination nod that stands to pad the ...
The case stems from ICIJ’s Cancer Calculus investigation into the world's best-selling drug’s sky-high price and its global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results